The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and ...

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Therapeutics), Application ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

The raised forecast reflects increases in the sales projections for a sweep of its current drugs – including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio – and more than 15 data readouts ...

These therapies, now part of Novartis’s portfolio, generated $1.8 billion in revenue in 2023, with Pluvicto alone projected to exceed $3 billion globally.

Learn about the executive team and board of directors at Novartis AG ADR (NVS:XNYS) and review their bios and compensation over the latest fiscal years.